Halfdan Sorbye

Summary

Affiliation: Haukeland University Hospital
Country: Norway

Publications

  1. doi request reprint Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients
    Halfdan Sorbye
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Cancer 115:4679-87. 2009
  2. doi request reprint Recurrence patterns after resection of liver metastases from colorectal cancer
    Halfdan Sorbye
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Recent Results Cancer Res 203:243-52. 2014
  3. doi request reprint Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer
    H Sorbye
    Department of Oncology, Haukeland University Hospital, Bergen, Denmark
    Ann Oncol 24:2354-60. 2013
  4. pmc Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab
    Janne B Kjersem
    Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
    BMC Cancer 12:534. 2012
  5. doi request reprint Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study
    H Sorbye
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Ann Oncol 24:152-60. 2013
  6. doi request reprint Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983)
    Halfdan Sorbye
    Haukeland University Hospital, Bergen, Norway
    Ann Surg 255:534-9. 2012
  7. ncbi request reprint [Palliative chemotherapy and radiotherapy for metastatic colorectal cancer]
    Halfdan Sørbye
    Kreftavdelingen Haukeland Universitetssjukehus, 5021 Bergen
    Tidsskr Nor Laegeforen 128:194-7. 2008
  8. doi request reprint Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
    Maria Thomsen
    Department of Oncology, Oslo University Hospital, Oslo, Norway
    Oncotarget . 2016
  9. doi request reprint Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study
    Kjell Magne Tveit
    Department of Oncology, Oslo University Hospital, 0407 Oslo, Norway
    J Clin Oncol 30:1755-62. 2012
  10. doi request reprint TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer
    Line S Tarpgaard
    Department of Oncology, Odense University Hospital, Odense, Denmark and University of Southern Denmark, Odense, Denmark
    Oncotarget . 2016

Collaborators

Detail Information

Publications19

  1. doi request reprint Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients
    Halfdan Sorbye
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Cancer 115:4679-87. 2009
    ..Trial accrual patterns were examined to determine whether metastatic colorectal cancer (mCRC) patients enrolled in trials are representative of a general cancer population concerning patient characteristics and survival...
  2. doi request reprint Recurrence patterns after resection of liver metastases from colorectal cancer
    Halfdan Sorbye
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Recent Results Cancer Res 203:243-52. 2014
    ..Perioperative chemotherapy reduces the risk of liver recurrence after hepatectomy of colorectal cancer liver metastases...
  3. doi request reprint Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer
    H Sorbye
    Department of Oncology, Haukeland University Hospital, Bergen, Denmark
    Ann Oncol 24:2354-60. 2013
    ..In metastatic colorectal cancer (mCRC) trials, median survival has increased from 6 months to above 20 months during the previous decades. Uncertainty exists in how this survival improvement has translated to the general mCRC population...
  4. pmc Let-7 miRNA-binding site polymorphism in the KRAS 3'UTR; colorectal cancer screening population prevalence and influence on clinical outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin +/- cetuximab
    Janne B Kjersem
    Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
    BMC Cancer 12:534. 2012
    ....
  5. doi request reprint Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study
    H Sorbye
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    Ann Oncol 24:152-60. 2013
    ..As studies on gastrointestinal neuroendocrine carcinoma (WHO G3) (GI-NEC) are limited, we reviewed clinical data to identify predictive and prognostic markers for advanced GI-NEC patients...
  6. doi request reprint Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983)
    Halfdan Sorbye
    Haukeland University Hospital, Bergen, Norway
    Ann Surg 255:534-9. 2012
    ..We conducted an exploratory retrospective analysis to identify baseline factors possibly predictive for a benefit of perioperative FOLFOX on PFS...
  7. ncbi request reprint [Palliative chemotherapy and radiotherapy for metastatic colorectal cancer]
    Halfdan Sørbye
    Kreftavdelingen Haukeland Universitetssjukehus, 5021 Bergen
    Tidsskr Nor Laegeforen 128:194-7. 2008
    ..There are 3 450 new cases of colorectal cancer in Norway annually. In half of the patients, metastatic disease will evolve with time. Palliative chemo- or radiotherapy can prolong disease- and symptom control when cure is not feasible...
  8. doi request reprint Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer
    Maria Thomsen
    Department of Oncology, Oslo University Hospital, Oslo, Norway
    Oncotarget . 2016
    ....
  9. doi request reprint Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study
    Kjell Magne Tveit
    Department of Oncology, Oslo University Hospital, 0407 Oslo, Norway
    J Clin Oncol 30:1755-62. 2012
    ..The influence of KRAS mutation status on treatment outcome was also investigated...
  10. doi request reprint TIMP-1 is under regulation of the EGF signaling axis and promotes an aggressive phenotype in KRAS-mutated colorectal cancer cells: A potential novel approach to the treatment of metastatic colorectal cancer
    Line S Tarpgaard
    Department of Oncology, Odense University Hospital, Odense, Denmark and University of Southern Denmark, Odense, Denmark
    Oncotarget . 2016
    ....
  11. doi request reprint Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab
    Line S Tarpgaard
    Department of Oncology, Odense University Hospital, Odense, Denmark
    Int J Cancer 137:2470-7. 2015
    ..These results thus support the preclinical findings and should be further tested in an independent clinical data set...
  12. pmc Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases
    Inger Marie Løes
    Department of Clinical Science, University of Bergen, Bergen, Norway
    Int J Cancer 139:647-56. 2016
    ..Our findings indicate that BRAF and KRAS mutations as well as mutation heterogeneity predict poor outcome in CRC patients subsequent to liver resections and might help guide treatment decisions. ..
  13. doi request reprint Review on adjuvant chemotherapy for rectal cancer - why do treatment guidelines differ so much?
    Laurids Ø Poulsen
    Department of Oncology, Aalborg University Hospital, Aalborg, Denmark
    Acta Oncol 54:437-46. 2015
    ..Both international and national guidelines display a great span varying from recommending no adjuvant chemotherapy at all, over single drug 5-fluororuacil (5-FU), to combinations of 5-FU/oxaliplatin...
  14. pmc Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study
    Line S Tarpgaard
    Department of Oncology, Odense University Hospital, Odense, Denmark and University of Southern Denmark, Odense, Denmark
    PLoS ONE 9:e87746. 2014
    ....
  15. pmc High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort
    Halfdan Sorbye
    Department of Oncology, Haukeland University Hospital, Bergen, Norway
    PLoS ONE 10:e0131046. 2015
    ..Lack of available tissue is an important underexposed issue which introduces sample bias, and this should be recognized more clearly when conclusions are made from translational mCRC studies. ..
  16. doi request reprint A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer
    Georg Dimcevski
    National Centre for Ultrasound in Gastroenterology, Haukeland University Hospital, Bergen, Norway Department of Clinical Medicine, University of Bergen, Bergen, Norway Electronic address
    J Control Release 243:172-181. 2016
    ..The secondary aim was to evaluate a novel image-guided microbubble-based therapy, based on commercially available technology, towards improving chemotherapeutic efficacy, preserving patient performance status, and prolonging survival...
  17. ncbi request reprint FLOX regimen (5-FU, folinic acid, oxaliplatin) and FLIRI regimen (5-FU, folinic acid, irinotecan) as first-line treatment in metastatic and locally advanced gastric cancer: A randomized phase II study
    Nils Glenjen
    Department of Oncology, Haukeland University Hospital, Bergen, Norway Department of Oncology, St Olavs Hospital, University of Trondheim, Trondheim, Norway Department of Oncology and Hematology, Stavanger University Hospital, Stavanger, Norway Department of Oncology, Oslo University Hospital, Oslo, Norway Centre for Clinical Reasearch, Haukeland University Hospital, Bergen, Norway Haukeland University Hospital, Bergen, Norway Institute of Medicine, University of Bergen, Bergen, Norway
    J Clin Oncol 30:71. 2012
    ..At progression or unacceptable drug related toxicity, a crossover to the other treatment arm should be done, if second line chemotherapy was indicated...
  18. pmc Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases
    Jon Helge Angelsen
    Department of Acute and Digestive Surgery, Haukeland University Hospital, N 5021, Bergen, Norway
    World J Surg Oncol 13:328. 2015
    ..We aimed to evaluate factors influencing time to recurrence (TTR), treatment and post-recurrence survival (PRS) related to site of recurrence...
  19. doi request reprint Small cell lung cancer in a 14-year-old girl
    Håvard Trønnes
    Department of Pediatrics, Haukeland University Hospital, Bergen, Norway
    J Pediatr Hematol Oncol 34:e86-8. 2012
    ..The patient died of relapsing disease 21 months after initial diagnosis. Only 1 single case report on SCLC has been published earlier. Additional reports on pediatric SCLC are needed to evaluate appropriate treatment...